EGFR and neoplasm: Based on our analysis shown in Tables 1 and 2, with ~1.2–5.1% of all breast cancers having an EGFR amplification, there would be ~1800–7650 patients whose tumor has EGFR amplification, with approximately half having a mutation in the PI3K pathway.